Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

21. ADHD

examination by a physician/medical doctor - Psychological 2016 10. Bupropion for attention deficit hyperactivity disorder ( ADHD ) in adults. BACKGROUND: Attention deficit hyperactivity disorder ( ADHD ) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although (...) in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact on family 2017 17. ADHD in Children and Adolescents ADHD in Children and Adolescents -- Clinical Recommendation Welcome Search Search Specify your search

2018 Trip Latest and Greatest

22. Association of Digital Media Use With Subsequent Symptoms of Attention-Deficit/Hyperactivity Disorder Among Adolescents. Full Text available with Trip Pro

Association of Digital Media Use With Subsequent Symptoms of Attention-Deficit/Hyperactivity Disorder Among Adolescents. Modern digital platforms are easily accessible and intensely stimulating; it is unknown whether frequent use of digital media may be associated with symptoms of attention-deficit/hyperactivity disorder (ADHD).To determine whether the frequency of using digital media among 15- and 16-year-olds without significant ADHD symptoms is associated with subsequent occurrence of ADHD (...) was defined as many times a day (yes/no) and was summed in a cumulative index (range, 0-14).Self-rated frequency of 18 ADHD symptoms (never/rare, sometimes, often, very often) in the 6 months preceding the survey. The total numbers of 9 inattentive symptoms (range, 0-9) and 9 hyperactive-impulsive symptoms (range, 0-9) that students rated as experiencing often or very often were calculated. Students who had reported experiencing often or very often 6 or more symptoms in either category were classified

2018 JAMA

23. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Full Text available with Trip Pro

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include stimulants such as methylphenidate and amphetamine; non-stimulants, such as atomoxetine; tricyclic (...) antidepressants; and alpha agonists. Alpha agonists are also used as a treatment for tics. Due to the impact of ADHD symptoms on the child with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades, clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics.  OBJECTIVES: To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms

2018 Cochrane

24. Stimulants for ADHD in children: Revisited

to a change in prescribing of stimulants to children in BC. Despite concerns, stimulant drug treatment of childhood at- tention-deficit/hyperactivity disorder (ADHD) has increased worldwide over the last two decades. 1 The optimal manage- ment of this behavioral condition remains unknown and this is reflected in the wide variation of stimulant treatment by country, jurisdiction, income, race and ethnicity. 1,2 Children are particularly vulnerable to harms of long- term drug therapies and there should (...) Letter 2008; 69:1-2. http://ti.ubc.ca/letter69 4. Storebø OJ, Ramstad E, Krogh HB, et al. Methylpheni- date for children and adolescents with attention deficit hy- peractivity disorder (ADHD). Cochrane Database of Sys- tematic Reviews 2015, Issue 11. Art. No.: CD009885. DOI: 10.1002/14651858.CD009885.pub2 5. Punja S, Shamseer L, Hartling L, et al. Amphetamines for atten- tion deficit hyperactivity disorder (ADHD) in children and adoles- cents. Cochrane Database of Systematic Reviews 2016, Issue 2

2018 Therapeutics Letter

25. Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study Full Text available with Trip Pro

Risk of suicide attempts in adolescents and young adults with attention-deficit hyperactivity disorder: a nationwide longitudinal study Attention-deficit hyperactivity disorder (ADHD) increases the risk of suicidal behaviours through psychiatric comorbidities; however, a significant direct association has not been observed between ADHD and suicide attempts. Aims To evaluate the risk of suicide attempt in adolescents and young adults with ADHD.Using a nationwide, population-based insurance (...) claims database, this longitudinal cohort study enrolled 20 574 adolescents and young adults with ADHD and 61 722 age- and gender-matched controls between 2001 and 2009. Any suicide attempt was identified from enrolment to 31 December 2011. The association between ADHD medications and the likelihood of suicide attempt was assessed.ADHD was an independent risk factor for any suicide attempt (hazard ratio = 3.84, 95% CI = 3.19-4.62) and repeated suicide attempts (hazard ratio = 6.52, 95% CI = 4.46-9.53

2018 EvidenceUpdates

26. Attention deficit hyperactivity disorder: diagnosis and management

this guideline into practice 51 Context 53 More information 54 Update information 55 Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 62This guideline replaces CG72 and TA98. This guideline is the basis of QS39. Ov Overview erview This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children (...) , young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD. Who is it for? Healthcare professionals Commissioners and providers People with ADHD, and their families and carers Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 62Recommendations Recommendations People

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

27. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents

, Ph.D. AHRQ Publication No. 18-EHC005-EF January 2018 ii Key Messages Purpose of Review To update a previous review by comparing strategies to diagnose, treat, and monitor children and adolescents with attention deficit hyperactivity disorder (ADHD). Key Messages • Evidence was insufficient on imaging or electroencephalogram to diagnose ADHD in children 7–17 years of age. • Little evidence adds to the 2011 report that found that methylphenidate is effective for children under age 6 with ADHD (...) . Harvard TH Chan School of Public Health Boston, MA Peter Jensen, M.D. Mayo Clinic Rochester, MN viii Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents Structured Abstract Objectives. Attention deficit hyperactivity disorder (ADHD) is a common pediatric neurobehavioral disorder often treated in the primary care setting. This systematic review updates and extends two previous Agency for Healthcare Research and Quality (AHRQ) systematic evidence reviews

2018 Effective Health Care Program (AHRQ)

28. Attention-deficit/hyperactivity disorder medication and seizures Full Text available with Trip Pro

Attention-deficit/hyperactivity disorder medication and seizures Individuals with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of seizures, but there is uncertainty about whether ADHD medication treatment increases risk among patients with and without preexisting seizures.We followed a sample of 801,838 patients with ADHD who had prescribed drug claims from the Truven Health MarketScan Commercial Claims and Encounters databases to examine whether ADHD medication (...) increases the likelihood of seizures among ADHD patients with and without a history of seizures. First, we assessed overall risk of seizures among patients with ADHD. Second, within-individual concurrent analyses assessed odds of seizure events during months when a patient with ADHD received ADHD medication compared with when the same individual did not, while adjusting for antiepileptic medications. Third, within-individual long-term analyses examined odds of seizure events in relation to the duration

2018 EvidenceUpdates

29. Computerized cognitive training in children and adolescents with attention deficit/hyperactivity disorder as add-on treatment to stimulants: feasibility study and protocol description. Full Text available with Trip Pro

Computerized cognitive training in children and adolescents with attention deficit/hyperactivity disorder as add-on treatment to stimulants: feasibility study and protocol description. Cognitive training has received increasing attention as a non-pharmacological approach for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents. Few studies have assessed cognitive training as add-on treatment to medication in randomized placebo controlled trials (...) . The purpose of this preliminary study was to explore the feasibility of implementing a computerized cognitive training program for ADHD in our environment, describe its main characteristics and potential efficacy in a small pilot study.Six ADHD patients aged 10-12-years old receiving stimulants and presenting residual symptoms were enrolled in a randomized clinical trial to either a standard cognitive training program or a controlled placebo condition for 12 weeks. The primary outcome was core ADHD

2018 Trends in psychiatry and psychotherapy Controlled trial quality: uncertain

30. Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Full Text available with Trip Pro

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Among US adults, utilization of pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) has increased more than ninefold since 1995-1996. Potential contraindications to ADHD pharmacotherapy include serious cardiovascular disease (CVD) and, for stimulants, addictions and bipolar disorder (BPD).To assess the prevalence (...) of potential contraindications among adults treated with ADHD pharmacotherapy.A retrospective cohort analysis was performed using the Truven Health MarketScan® database. Subjects filled ≥ 1 prescription for atomoxetine or ≥ 1 stimulant in 2014-2015, were aged 18-64 years, commercially insured throughout observation, and diagnosed with ADHD on two or more medical claims. Diagnoses and medical procedures were measured in the 12 months prior to pharmacotherapy initiation. Metrics included serious CVD

2018 Drugs - real world outcomes

31. Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

2014, four systematic reviews (including pairwise meta-analyses and network meta-analyses of direct and indirect evidence), one randomized controlled trial, and one guideline have been published regarding the use of guanfacine hydrochloride extended-release (GXR) for the treatment of attention deficit-hyperactivity disorder (ADHD) in children and adolescents.All included studies reported significant improvements in subjective ADHD rating scales as well as scales in executive function when using GXR (...) Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

32. Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

controlled trial suggested that guanfacine hydrochloride extended-release (GXR) was safe and well-tolerated when added to an existing psychostimulant treatment for adults with attention deficit hyperactivity disorder (ADHD). However, GXR did not differ from placebo with respect to clinical effectiveness. No evidence for the cost-effectiveness of GXR for the treatment of adults with ADHD was identified. One evidence-based guideline from the United Kingdom was identified that provides recommendations (...) Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

33. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. (Abstract)

Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. Prefrontal-limbic circuits that form the neural architecture for emotion to influence behavior have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and represent a potentially important target of medication treatment that has not been substantively evaluated. This study tested the effect of the psychostimulant prodrug lisdexamfetamine (...) dimesylate on amygdala activation and connectivity during the emotional bias of response execution and inhibition.Twenty-five adults with ADHD were scanned twice with event-related functional magnetic resonance imaging while performing an emotional go/no-go task after 3 to 4 weeks of lisdexamfetamine treatment and 3 weeks off medication in a randomized, counterbalanced, hybrid crossover design. Drug, trial type, and face emotion (happy, sad, or neutral) were included as within-subjects factors

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain

34. Attention deficit hyperactivity disorder in adults

Attention deficit hyperactivity disorder in adults Attention deficit hyperactivity disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in adults Last reviewed: February 2019 Last updated: October 2018 Summary A common adult disorder, thought to be persistence of childhood attention deficit hyperactivity disorder (ADHD). Prevalence of 2% to 5% in the general (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

35. Attention deficit hyperactivity disorder in children

of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013. As a result, ADHD can limit academic, interpersonal, and occupational success and can also lead to greater risk-taking and accidents. Schonwald A, Lechner E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr. 2006;18:189-195. http://www.ncbi.nlm.nih.gov/pubmed/16601502?tool=bestpractice.com In addition, patients with ADHD are more likely to have co-existing psychiatric (...) Attention deficit hyperactivity disorder in children Attention deficit hyperactivity disorder in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in children Last reviewed: February 2019 Last updated: March 2018 Summary Common childhood-onset disorder characterised by inattention, hyperactivity, and/or impulsivity demonstrated across 2 or more settings (such as home

2018 BMJ Best Practice

36. Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder - NICE CKS Share Attention deficit hyperactivity disorder: Summary Attention deficit hyperactivity disorder (ADHD) is a behavioural syndrome characterized by hyperactivity, impulsivity, and inattention. ADHD should be suspected if the core symptoms of hyperactivity, inattention, and/or impulsivity have been present since childhood. These core symptoms are age-inappropriate and result in significant psychological (...) to 60 years. This CKS topic is based on the National Institute for Health and Care Excellence guideline Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults [ ]. This CKS topic covers the diagnosis, assessment, and management in primary care of suspected attention deficit hyperactivity disorder (ADHD) in children, young people, and adults. This CKS topic does not cover in detail the diagnosis and management of ADHD by specialists

2018 NICE Clinical Knowledge Summaries

37. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward Full Text available with Trip Pro

Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward Article Text Clinical review Twenty years of research on attention

2018 Evidence-Based Mental Health

38. Causes and risk factors: Pharmacological treatment reduces the risk of motor vehicle crashes among men and women with ADHD

treatment reduces the risk of motor vehicle crashes among men and women with ADHD Aida Bikic 1 , Søren Dalsgaard 2 Statistics from Altmetric.com COMMENTARY ON: Chang Z, Quinn PD, Hur K, Gibbons RD, Sjölander A, Larsson H & D’Onofrio. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017;74(6):597–603. What is already known on this topic Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder (...) with core symptoms of inattention, hyperactivity and impulsivity,; traits that may increase the risk of injuries and motor vehicle crashes (MVCs). Injuries in early childhood predict later ADHD, 1 a diagnosis that is associated with a twofold increased risk of premature death, with accidents being the most common cause of death. 2 ADHD is commonly treated with pharmacotherapy that successfully targets most of the impairing core symptoms. 3 In children with ADHD, pharmacological treatment also reduces

2018 Evidence-Based Mental Health

39. Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Full Text available with Trip Pro

Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects children, adolescents, and adults worldwide. The purpose of this review was to inform pharmacists of the numerous options to treat ADHD, with a focus on one of the more recently approved formulations, methylphenidate extended-release oral suspension (MEROS (...) ). Symptoms of ADHD can negatively impact an individual's health and quality of life and impair function in multiple settings. Psychostimulants such as methylphenidate- and amphetamine-based agents are first-line pharmacologic treatments for ADHD. However, there are multiple formulations, including immediate release (administered two to three times/day), solid extended release (ER), or transdermal patch. MEROS is a once daily, long-acting liquid preparation that has demonstrated favorable safety

2017 Integrated pharmacy research & practice

40. Attention deficit hyperactivity disorder (ADHD): avoid guanfacine

hyperactivity disorder (ADHD): avoid guanfacine In children diagnosed with attention deficit hyperactivity disorder (ADHD), guanfacine has no proven efficacy in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact (...) Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Prescrire IN ENGLISH - Spotlight ''Attention deficit hyperactivity disorder (ADHD): avoid guanfacine'', 1 October 2017 {1} {1} {1} | | > > > Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Attention deficit

2017 Prescrire